Back to resultsMK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED)
Primary Purpose
Seasonal Allergies
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
MK0524
Sponsored by
About this trial
This is an interventional treatment trial for Seasonal Allergies
Eligibility Criteria
Inclusion Criteria:
- Person has had at least 2 years of seasonal allergies
- Person has had a positive skin test to at least 1 of the allergens of the season
- Person is a non-smoker
Exclusion Criteria:
- Person has been hospitalized within the last 4 weeks
- Person is a female who has had a baby within the last 8 weeks or is still breast-feeding
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00533208
First Posted
September 19, 2007
Last Updated
December 21, 2015
Sponsor
Merck Sharp & Dohme LLC
1. Study Identification
Unique Protocol Identification Number
NCT00533208
Brief Title
MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED)
Study Type
Interventional
2. Study Status
Record Verification Date
December 2015
Overall Recruitment Status
Completed
Study Start Date
July 2003 (undefined)
Primary Completion Date
October 2003 (Actual)
Study Completion Date
October 2003 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck Sharp & Dohme LLC
4. Oversight
5. Study Description
Brief Summary
To assess the efficacy of MK0524 on seasonal allergies.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Seasonal Allergies
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
766 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
MK0524
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Person has had at least 2 years of seasonal allergies
Person has had a positive skin test to at least 1 of the allergens of the season
Person is a non-smoker
Exclusion Criteria:
Person has been hospitalized within the last 4 weeks
Person is a female who has had a baby within the last 8 weeks or is still breast-feeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Merck Sharp & Dohme LLC
Official's Role
Study Director
12. IPD Sharing Statement
Citations:
PubMed Identifier
19748656
Citation
Philip G, van Adelsberg J, Loeys T, Liu N, Wong P, Lai E, Dass SB, Reiss TF. Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. J Allergy Clin Immunol. 2009 Nov;124(5):942-8.e1-9. doi: 10.1016/j.jaci.2009.07.006. Epub 2009 Sep 12.
Results Reference
derived
Learn more about this trial
MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED)
We'll reach out to this number within 24 hrs